Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Jason Gyamfi did it first. In early November, the 21-year-old TikTok creator posted a video of himself and a friend sipping matchas from the VC-funded coffee chain Blank Street and wearing navy ...
Jason Fernando is a professional investor and writer who enjoys tackling and communicating complex business and financial problems. David Kindness is a Certified Public Accountant (CPA) and an expert ...
Caroline Banton has 6+ years of experience as a writer of business and finance articles. She also writes biographies for Story Terrace. Investopedia / Paige McLaughlin Quarter over quarter (Q/Q) ...
Krugerrand 1/2 oz 1,821.50 1.79 CHF per 1/2 Ounce 1/12/26 11:00 AM Popular Articles Copyright © 2025 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback